New derivatives of pyrrolo[3,4-d]pyridazinone and their anticancer effects

Farmaco

Volumn 59, Issue 6, 2004, Pages 457-462

  Malinka, Wiesław ^a   Redzicka, Aleksandra ^a   Lozach, Olivier ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b STATION BIOLOGIQUE   (France)

Author keywords

Anticancer screening; Pyrrolo 3,4 d pyridazinones; Synthesis

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMICAL COMPOUND; CYCLIN B; PHOSPHOTRANSFERASE; PYRIDAZINONE DERIVATIVE; PYRROLO[3,4 D]PYRIDAZINONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME REGULATION; HUMAN; HUMAN CELL; INFRARED RADIATION; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG SCREENING ASSAYS, ANTITUMOR; FRANCE; HUMANS; MOLECULAR STRUCTURE; PROTEIN KINASES; PYRIDAZINES; PYRROLES; STARFISH; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2642517789     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2004.03.002     Document Type: Article

References (19)

1. Meade E.A., Wotrin L.L., Drach J.C., Townsend L.B. Synthesis, antiproliferative and antiviral activity of 4-amino-1(β-D-ribofuranosyl) pyrrolo[2, 3-d]pyridazin-7(6H)-one and related derivatives. J. Med. Chem. 36:1993;3834-3842
2. Meade E.A., Wotrin L.L., Drach J.C., Townsend L.B. Synthesis and antiproliferative and antiviral activity of carbohydrate modified pyrrolo[2, 3-d]pyridazin-7-one nucleosides. J. Med. Chem. 40:1997;794-801
3. Kimura T., Fujihara Y., Shibakawa N., Fuijwara H., Itoh E., Matsunobu K., et al. Preparation of pyrrolopyridazine derivatives having antibacterial activity against Helicobacter pylori as antiulcer agents. 1996;. PCT Int,. Appl. WO 95 19, 980; C.A., 124 8849h
4. Grundler G., Senn-Bilfinger J., Schaefer H., Rainer G., Klemm K., Simon W.A., et al. Preparation of benzyl (arylalkoxy)pyrrolopyridazines as ulcer inhibitors. 1992;. PCT Int,. Appl. WO 92 06, 979; C.A., 117 111632m
5. Grundler G., Rainer G., Schaefer H., Senn-Bilfinger J., Klemm K., Simon W.A., et al. Pyrrolopyridazines with gastrointestinal protective action. 1993;. PCT Int,. Appl. WO 93 08, 190; C.A., 119 180803w
6. Iwabuchi H., Hagihara M., Shibakawa N., Matsunobu K., Fujiwara H. Preparation of pyrrolopyridazine derivatives as antiulcer agents. 2001;. PCT Int,. Appl. WO 2001058901 Al. 16 Aug 2001; 84 pp; C.A., 135 180774t
7. Hagihara M., Shibakawa N., Matsunobu K., Fujiwara H., Keiichi I. Preparation of optically active pyrrolopyridazine compounds as antiulcer agents. 2001;. PCT Int,. Appl. WO 2000077003 Al. 21 Dec 2000; 42pp; C.A., 134 56679f
8. Kulagowski J.J., Lesson P.D. 4-Hydroxypyrrolo[1, 2-b]pyridazin-2(1H)-one NMDA and AMPA receptor antagonist. 1994;. Brit. UK Pat. Appl. GB 2, 265, 372; C.A., 120 134504x
9. Ungureanu M., Mangalagiu I., Grasu G., Petrovanu M. Antimicrobial activity some new pyridazinum compounds. Annal Pharm Franc. 55:1997;69-72
10. Mitsuaki O., Masahiro F., Yoshikazu F., Makoto A. Preparation of pyrrolo[1, 2-b]pyridazine derivatives havings PLA2 (secretory phospholipase A2) inhibitory effect. 1999;. PCT Int,. Appl. WO 9959999 Al. 25 Nov 1999, 109 pp; C.A., 131 286537a
11. Ostby O.B., Gunderson L.-L., Rise F., Antonsen O., Fosnes K., Larsen V., et al. Synthesis of 5-substituted pyrrolo[1, 2-b]pyridazines with antioxidant properties. Arch. Pharm. Pharm. Med. Chem. 334:2001;21-24
12. Malinka W. Synthesis of some pyrrolo[3, 4-d]pyridazinones and their preliminary anticancer, antimycobacterial and CNS screening. Pharmazie. 56:2001;384-389
13. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Nat. Cancer Inst. 83:1991;757-766
14. Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536
15. Malinka W., Bodalski T. Synthesis of some 1-substituted-2, 5-dimethylpyrrole-3, 4-dicarboximides from α, β-diacetylsuccinate. Pol. J. Chem. 68:1994;297-307
16. Kochel A., Malinka W., Redzicka A. Crystal structure of 1, 2, 3, 4-tetrahydro-2, 6-diphenyl-3, 5, 7-trimethyl-6H-pyrrolo[3, 4-d]pyridazine-14- dione, C19H19N3O2. Z. Kristallog. NCS. 218:2003;1-2
17. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trend. Pharmacol. Sci. 23:2002;417-425
18. Mettey Y., Gompel M., Thomas V., Garnier M., Leost M., Ceballos-Picot I., et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 46:2003;222-236
19. cdc2 on its Thr-14 and Tyr-15 residues at the prophase/metaphase transition. J. Biol. Chem. 271:1996;27847-27854